Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
ORR of 50% and median PFS of 11.8 months in patients with KRAS mutant advanced colorectal cancer (CRC) treated in the second-line Favorable safety profile with a majority of TEAEs Grade 2 or lower, and no DLTs observed Overall efficacy and safety